Perros, P.

Wiersinga, W.M.

English

International Migration, Integration and Social Cohesion online publications

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)UvA-DARE (Digital Academic Repository)The Amsterdam Declaration on Graves' OrbitopathyPerros, P.; Wiersinga, W.M.DOI10.1089=thy.2010.1618Publication date2010Document VersionFinal published versionPublished inThyriodLink to publicationCitation for published version (APA):Perros, P., & Wiersinga, W. M. (2010). The Amsterdam Declaration on Graves' Orbitopathy.Thyriod, 20(3), 245-246. https://doi.org/10.1089=thy.2010.1618General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s)and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an opencontent license (like Creative Commons).Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, pleaselet the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the materialinaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letterto: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. Youwill be contacted as soon as possible.Download date:09 Mar 2023COMMENTARYThe Amsterdam Declaration on Graves’ OrbitopathyPetros Perros1 and Wilmar M. Wiersinga2‘‘The pathogenesis of Graves’ orbitopathy is still poorly understood. Through research into the normal and abnormal situations,approached by different disciplines, might elucidate the problems and enable better management to prevent this disfiguring disease.’’This statement holds true now as it did nearly 20 yearsago (1). Some patients have an excellent outcome, whileothers may suffer a long and debilitating illness. Those whodo well are not the recipients of new breakthroughs in treat-ment. The variance in outcome is to some extent a reflection ofinequalities in availability of expertise and delivery of medicaland surgical treatments that have changed little for decades(2,3).FIG. 1. Signatories of the Amsterdam Declaration on Graves’ Orbitopathy, October 30, 2009. Front row from left to right:Professor S. Gullu (Turkish Society for Endocrinology and Metabolism), Dr. P. Perros (European Group on Graves’ Orbi-topathy), Professor J. Lazarus (Society for Endocrinology, UK and British Thyroid Association), Dr. M. Salvi (Italian ThyroidPatient Association), Dr. U. Slama (Finish Thyroid Foundation), Dr. Y. Inoue ( Japan Thyroid Association), Dr. C. Dayan(Thyroid Eye Disease Charitable Trust), Professor M. Alevizaki (European Society of Endocrinology), Professor C. Daumerie(Belgian Endocrine Society and Belgian Thyroid Club), Professor L. Bartalena (Italian Society of Endocrinology), Ms. L. van ‘tRiet (Schildklierstichting Nederland), Dr. C. Schalin-Jantti (Finnish Endocrine Society), Mrs. J. Hickey (British ThyroidFoundation), Mr. N. de Jong (Nederlandse Vereniging van Graves’ patienten). Back row from left to right: Dr. C. Lane(British Oculoplastic Surgery Society), D. O. Vonica (Romanian Society for Endocrinology), Professor T. Davies (AmericanThyroid Association), Dr. P. Dolman (International Thyroid Eye Disease Study Group), Dr. H. Ramos (Latin America ThyroidSociety), Professor M. Mourits (European Society of Orbital Plastic Reconstructive Surgery), Professor G. Krassas (HellenicEndocrine Society), Professor W. Wiersinga (European Group On Graves’ Orbitopathy), Dr. G. von Arx (Verein Schild-drüsengruppe Schweiz), Dr. A. Eckstein (Bielschowsky-Gesellschaft für Schielforschung und Neuroophthalmologie), Dr. L.de Heide (Dutch Endocrine Society), Dr. C. Marcocci (Italian Thyroid Association), Professor J Orgiazzi (French EndocrineSociety), Dr. E. Nyström (Thyroid Federation International), Professor P. Laurberg (European Thyroid Association), ProfessorG. Kahaly (German Endocrine Society and German Thyroid Board), Professor R. Bahn (Endocrine Society), Professor C.Hintschich (German Society of Ophthalmology), Dr. L. Baldeschi (Italian Society of Ophthalmic Plastic Surgery).1Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.2Department of Endocrinology and Metabolism, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.THYROIDVolume 20, Number 3, 2010ª Mary Ann Liebert, Inc.DOI: 10.1089=thy.2010.1618245Similar considerations drove clinicians, patients, and poli-ticians to formulate the St. Vincent declaration for people withdiabetes (4). The St. Vincent Declaration was daring and as itturned out overambitious in its proposed timeframe forchange, but it was ultimately a success. It brought diabetes tothe top of the agenda for health providers, health economists,and clinicians. It provided the leverage required to improvediabetes care, not through exotic new treatments, but bybuilding the infrastructure necessary to allow healthcare toreach those who needed it.The parallels between care delivery in diabetes and Graves’orbitopathy (GO) inspired the Amsterdam Declaration, whichappears in this issue (see page 351) (5). This document high-lights that patients with GO can and should receive bettercare. It draws attention to improving quality of life of pa-tients, prevention, and swifter care, preferably in centers ofexcellence. It also sets specific 5-year targets for health careproviders.A few months ago this vision was put forward to interna-tional and national professional societies and thyroid patientorganizations. The response has exceeded all expectations. Onthe October 30, 2009, during the 10th International Sympo-sium on Graves’ Orbitopathy, the Amsterdam Declarationwas signed (Fig. 1). To date, the Amsterdam Declaration hasbeen signed by representatives of 82 organizations includingall the sister thyroid associations, 15 international professionalsocieties, 44 national professional societies, and 23 patient-ledorganizations (see Notice on page 351) (5).So, the principles and concept have been firmly agreedupon. Now the hard work begins!References1. Koornneef L, Schmidt ED, van der Gaag R 1990 The orbit:structure, autoantigens and pathology. In: Wall JR, How J(eds) Graves’ Ophthalmopathy. Blackwell Scientific Pub-lications, Philadelphia, PA, pp 1–16.2. Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A,Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, LazarusJH, Marcocci C, Marino M, Mourits MP, Nardi M, Orgiazzi J,Pinchera A, Pitz S, Prummel MF, Wiersinga WMA 2006 Aquestionnaire survey on the management of Graves’ orbi-topathy in Europe. Eur J Endocrinol 155:207–211.3. Ramos HE, Diehl LA, Camacho CP, Perros P, Graf H 2008Management of Graves’ orbitopathy in Latin America: aninternational questionnaire study compared with Europe.Clin Endocrinol (Oxf ) 69:951–956.4. Krans HMJ, Porta N, Keen H (eds) 1992 Diabetes Care andResearch in Europe: The St Vincent Declaration ActionProgramme. Copenhagen: World Health Organisation Re-gional Office for Europe.5. Graves’ orbitopathy: Improving outcomes for thyroid eyedisease—The Amsterdam Declaration. 2010. Thyroid 20:351–352.Address correspondence to:Petros PerrosDepartment of EndocrinologyRoyal Victoria InfirmaryNewcastle upon Tyne NE1 4LPUnited KingdomE-mail: petros.perros@ncl.ac.uk246 COMMENTARYThis article has been cited by:

The Amsterdam Declaration on Graves' Orbitopathy

https://pure.uva.nl/ws/files/1457381/97709_340922.pdf

The Amsterdam Declaration on Graves' Orbitopathy

Abstract

Similar works

Full text

Available Versions

International Migration, Integration and Social Cohesion online publications